Literature DB >> 22771126

Reporting of funding sources and conflict of interest in the supportive and palliative oncology literature.

David Hui1, Akhila Reddy, Henrique A Parsons, Eduardo Bruera.   

Abstract

CONTEXT: The reporting of funding support and conflict of interest has not been examined in the supportive/palliative oncology literature.
OBJECTIVES: We examined the frequency of funding and conflict of interest reporting and various study characteristics associated with such reporting.
METHODS: We systematically searched MEDLINE PubMed, PsycInfo, EMBASE, ISI Web of Science, and CINAHL for original studies related to palliative care and cancer in the first six months of 2004 and 2009. For each article, we reviewed the study design, research topic, journal type, and reporting of funding and conflict of interest.
RESULTS: Three hundred forty-four (41%) and 504 (59%) of 848 articles were from 2004 and 2009, respectively. Five hundred two of 848 (59%) studies reported no funding sources, whereas 216 (26%), 70 (8%), 34 (4%), and 26 (3%) reported one, two, three, and four or more sources, respectively. Key funding sources included governmental agencies (n=182/848, 21%), philanthropic foundations (n=163/848, 19%), university departments (n=76/848, 9%), and industry (n=27/848, 3%). Conflict of interest was not reported in 436 of 848 (51%) studies, and only 94 of 848 (11%) explicitly stated no conflict of interest. Other than extramural funding, conflict of interest reporting of any kind was extremely rare (mostly less than 1%). Conflict of interest reporting increased between 2004 and 2009 (39% vs. 55%, P<0.001). Both funding and conflict of interest reporting were associated with prospective studies, larger sample sizes, nontherapeutic studies, North American authors, and publication in palliative care/oncology journals (P≤0.008 for all comparisons).
CONCLUSION: A majority of supportive/palliative oncology studies did not report funding sources and conflict of interest, raising the need for standardization.
Copyright © 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22771126      PMCID: PMC3905444          DOI: 10.1016/j.jpainsymman.2011.09.016

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  27 in total

1.  The quest to fund research: playing research lotto.

Authors:  Michelle Cleary; Garry Walter; Glenn Hunt
Journal:  Australas Psychiatry       Date:  2006-09       Impact factor: 1.369

2.  The future of funding for palliative care research: suggestions for our field.

Authors:  J Randall Curtis; R Sean Morrison
Journal:  J Palliat Med       Date:  2009-01       Impact factor: 2.947

3.  Changes in the quantity and level of evidence of palliative and hospice care literature: the last century.

Authors:  Jennifer Tieman; Ruth Sladek; David Currow
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

4.  Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.

Authors:  Susannah L Rose; Monika K Krzyzanowska; Steven Joffe
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

Review 5.  Industry sponsorship and selection of comparators in randomized clinical trials.

Authors:  D N Lathyris; N A Patsopoulos; G Salanti; J P A Ioannidis
Journal:  Eur J Clin Invest       Date:  2009-12-27       Impact factor: 4.686

Review 6.  The role of conflict of interest in reporting of scientific information.

Authors:  Richard S Irwin
Journal:  Chest       Date:  2009-07       Impact factor: 9.410

Review 7.  Research funding for palliative medicine.

Authors:  Laura P Gelfman; R Sean Morrison
Journal:  J Palliat Med       Date:  2008 Jan-Feb       Impact factor: 2.947

8.  Transdermal fentanyl: not ready for front line.

Authors:  David Hui; Eduardo Bruera
Journal:  J Palliat Care       Date:  2009       Impact factor: 2.250

9.  Evolution of the randomized controlled trial in oncology over three decades.

Authors:  Christopher M Booth; David W Cescon; Lisa Wang; Ian F Tannock; Monika K Krzyzanowska
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

Review 10.  Conflicts of interest: how money clouds objectivity.

Authors:  Richard Smith
Journal:  J R Soc Med       Date:  2006-06       Impact factor: 18.000

View more
  7 in total

Review 1.  Which treatment is better? Ascertaining patient preferences with crossover randomized controlled trials.

Authors:  David Hui; Donna S Zhukovsky; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2014-12-30       Impact factor: 3.612

Review 2.  Integrating palliative care into the trajectory of cancer care.

Authors:  David Hui; Eduardo Bruera
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 3.  The last days of life: symptom burden and impact on nutrition and hydration in cancer patients.

Authors:  David Hui; Rony Dev; Eduardo Bruera
Journal:  Curr Opin Support Palliat Care       Date:  2015-12       Impact factor: 2.302

4.  Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials.

Authors:  David Hui; Isabella Glitza; Gary Chisholm; Sriram Yennu; Eduardo Bruera
Journal:  Cancer       Date:  2012-11-06       Impact factor: 6.860

5.  Quality of Author Guidelines in Nursing Journals.

Authors:  Marilyn H Oermann; Leslie H Nicoll; Peggy L Chinn; Jamie L Conklin; Midori McCarty; Sathya Amarasekara
Journal:  J Nurs Scholarsh       Date:  2018-04-12       Impact factor: 3.176

Review 6.  An Evidence Map of the Women Veterans' Health Research Literature (2008-2015).

Authors:  Elisheva R Danan; Erin E Krebs; Kristine Ensrud; Eva Koeller; Roderick MacDonald; Tina Velasquez; Nancy Greer; Timothy J Wilt
Journal:  J Gen Intern Med       Date:  2017-09-14       Impact factor: 5.128

7.  Reporting of adverse events, conflict of interest and funding in randomised controlled trials of antibiotics: a secondary analysis.

Authors:  Mina Bakhit; Mark Jones; Jenalle Baker; Ramil Nair; Kylie Yan; Chris Del Mar; Anna Mae Scott
Journal:  BMJ Open       Date:  2021-07-20       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.